Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Week in Review: Baidu Raising $2 Billion for New China Biopharma

Deals and Financings   Baidu, a major China internet/AI company, is raising $2 billion to fund a new China drug development and diagnostics company; Huadong Medicine partnered with Exscientia, a UK drug discovery company based on AI, to identify novel small-molecule candidates for oncology; CANbridge Pharma of Beijing formed a second gene therapy collaboration with UMass to use virus vectors to treat neuromuscular diseases; Hualan Genetic Engineering will develop three Harbour BioMed novel antibodies in return for China marketing rights to the candidates; An Ascletis subsidiary partnered with Israel 's Galmed Pharma to test a combination therapy for NASH; Trials and Approvals   Zai Lab of Shanghai announced China approval of a new indication for its PARP inhibitor --  first-line maintenance therapy for ovarian cancer; Beijing 's CANbridge Pharma was approved to launch Hunterase® in China for Hunter syndrome, a rare disease; Junshi Bio of Shanghai reported the US FDA granted Breakthrough Designation to its PD-1 for nasopharyngeal carcinoma; Everest Medicines, a Shanghai biopharma, began dosing patients in a China Phase III trial of a treatment for autoimmune renal disease; Zion Pharma, headquartered in Hong Kong , started a US Phase I trial of its novel HER2 inhibitor that is aimed at the brain metastases of HER2+ breast cancer. Stock Symbols: (NSDQ: BIDU) (SHZ: 0963) (HK: 1672) (NSDQ: GLMD) (NSDQ: ZLAB) (HK: 1877; SHA: 688180) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.